Skip to content
Peptide Atlas
All peptides

MOTS-c

Tier 2 · Preclinical
Also known as MOTSc · Mitochondrial ORF of the 12S rRNA type-c

The strongest human evidence is CohBar's Phase 1a/1b randomized, double-blind, placebo-controlled study (src-1) — but it tested CB4211, a MOTS-c analog rather than native MOTS-c, with a small Phase 1b treatment group (n=11 vs n=9 placebo; total enrollment 88). A Phase 2a study in prediabetes/overweight adults is described as recruiting (src-5). Beyond this, essentially all efficacy findings come from animal models, in vitro work, human observational associations, expert opinion and one 2025 preprint (src-6). Multiple sources state there are no patient trials with native MOTS-c and that no clinical application method has been developed (src-2, src-3, src-17). Some specific quantitative figures originate from a single tier-3 clinic analysis (src-10) and are not corroborated by higher-tier sources.

Half-life
Not recorded
Routes
Subcutaneous injection (human protocols, src-2, src-9, src-16) · Intraperitoneal injection (animal studies, src-4, src-25) · Intracerebroventricular / carrier-coupled intranasal (animal cognition studies, src-12)
Goals
Metabolic health / insulin sensitivity · Weight / fat loss · Exercise performance and recovery · Longevity / healthy aging
Cost / mg
Not recorded

How it works

MOTS-c is a small 16-amino-acid peptide that, according to vendor and review sources, is encoded inside mitochondrial DNA and was discovered in 2015. Several sources describe it as a 'mitokine' — a signal that reports on mitochondrial health. Its most studied action, per multiple sources, is switching on AMPK, a cellular energy sensor that tells cells to burn fuel more efficiently, become more sensitive to insulin, and resist storing energy as fat. Under stress (low glucose, oxidative stress) sources report the peptide moves into the cell nucleus and turns on antioxidant and adaptive stress-response genes. Because exercise naturally raises MOTS-c and the peptide reproduces several exercise-like effects in animals, sources frequently describe it as an 'exercise-mimetic.'

Overview

What MOTS-c is

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is described across sources as a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene. A clinic press article (src-5) states it was first described in 2015 by researchers at the USC Leonard Davis School of Gerontology with collaborators at UCLA and the NIH. A peptide blog (src-11) reports it was first characterized in 2015 by Lee and colleagues, who showed stressed muscle cells release it so it can translocate to the nucleus and upregulate adaptive stress-resistance genes (sequence M-R-W-Q-Q-T-G-I-F-S-M-S-G-W-L-P). The ADDF review (src-12) gives its formula as C101H152N28O22S2 (MW 2174.6 g/mol). A 2025 study (src-4) reports it is widely expressed across tissues (brain, heart, liver, muscle, testis, kidney, gut and plasma) in rodents and humans.

Several sources characterize MOTS-c as a 'mitokine' that reports mitochondrial health and, according to a pharmacy blog (src-14), orchestrates systemic responses via AMPK activation. Health.com (src-3) describes it as an injectable peptide meant to mimic the effects of exercise, and a 2022 review (src-21) calls it the mitochondrial-derived peptide most associated with exercise, noting its expression increases in skeletal muscle, systemic circulation and the hypothalamus upon exercise. A 2021 review (src-30) describes it as an exercise-sensitive myokine with exercise-mimetic properties.

What the human evidence shows

Human evidence is very limited and largely derives from a MOTS-c analog, not native MOTS-c. CohBar reports (src-1) that its Phase 1a/1b study of CB4211 — Phase 1a being a double-blind, placebo-controlled single- and multiple-ascending-dose safety/PK assessment, and Phase 1b a randomized, double-blind, placebo-controlled evaluation of one dose given once daily for four weeks in obese subjects with NAFLD — enrolled 88 total (11 CB4211, 9 placebo) and ran from July 2018 to April 2021. CohBar reports the 25 mg once-daily dose produced a 21% ALT reduction from baseline versus 4% placebo and a 28% AST reduction versus 11% placebo (p<0.05), a 6% glucose reduction versus 0% placebo (p<0.05), and a trend toward lower body weight. However, CohBar also reports the liver-fat responder rate (36% for >30% relative reduction) was only marginally above placebo (33%), with similar absolute liver-fat reductions (5.03% vs 4.88%). A clinic analysis (src-10) summarizes this as the only small human trial (20 subjects, CB4211, an analog rather than native MOTS-c). A clinic press article (src-5) states a Phase 2a study in adults with prediabetes and overweight/obesity is recruiting. Multiple sources (src-2, src-3, src-17) emphasize there are no patient trials with native MOTS-c, that human observational samples are under 30 and not placebo-controlled at definitive scale, and that no clinical application method has been developed.

Human observational data include reports (src-4, src-28, src-49) that MOTS-c expression is decreased in type 2 diabetes patients and declines with age (src-10 states 21% lower in 70-81 year-olds and notes Japanese centenarians harbor beneficial variants), that Health.com (src-3) links lower MOTS-c levels to components of metabolic syndrome, and that a 2024 study (src-19) found reduced serum and tumor MOTS-c in ovarian cancer patients associated with poor prognosis. A 2025 study (src-24) reports serum MOTS-c increments within 24 hours post-cardiopulmonary bypass predicted ARDS incidence (AUC=0.885). A clinic analysis (src-10) states exercise increases endogenous muscle MOTS-c 12-fold — a figure from a single low-tier source.

What the preclinical evidence shows

Animal and in vitro findings dominate. The 2015 study (src-18) reports MOTS-c prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice. A vendor resource (src-2) states that in high-fat-diet mice MOTS-c improves insulin sensitivity, reduces fat mass and prevents obesity, with replication by multiple groups. src-4 reports intraperitoneal MOTS-c in fed mice reduced blood glucose and visceral fat similarly to aerobic exercise, and in vitro increased fatty acid utilization. Additional animal/in vitro findings include improved T2DM-induced liver fibrosis via a Keap1-Nrf2-Smad2/3 mechanism (src-4), alleviation of gestational-diabetes hyperglycemia and β-cell protection (src-20, src-73), prevention of muscle atrophy and myostatin reduction (~40%, p<0.05) via a CK2-PTEN-mTORC2-AKT-FOXO1 pathway (src-10, src-51), anti-tumor effects on ovarian cancer without systemic toxicity (src-19, src-71), endothelial protection in lung ischemia-reperfusion injury (src-24), and improved exercise capacity in young and aged mice (src-30). A clinic analysis (src-10) cites 12-15% single-dose performance gains and 100% vs 16.6% treadmill completion, and 6-7% lifespan trends — figures from a single low-tier source.

Mechanistically, sources converge on AMPK activation (src-10, src-12, src-14, src-18, src-41) with nuclear translocation under stress engaging NRF2/antioxidant gene programs (src-23, src-24). Cognitive effects are delivery-dependent: the ADDF review (src-12) reports peripheral MOTS-c had no cognitive effect in mice and that MOTS-c is not blood-brain-barrier penetrant, with memory protection seen only via intracerebroventricular or carrier-coupled intranasal delivery.

Proposed and investigational uses

Health.com (src-3) states MOTS-c is being evaluated for obesity and osteoporosis and is mainly studied for metabolism, insulin resistance and slower aging. Innerbody (src-13) describes it as a peptide that may help extend lifespan and improve metabolism while maintaining muscle and losing fat. A 2025 preprint (src-6) proposes MOTS-c for ME/CFS on a mitochondrial-dysfunction rationale but itself states human safety and efficacy data are lacking. Review sources also raise theoretical roles in retinal disease/AMD (src-8, src-26). These remain investigational — a 2023 review (src-17) states no effective method of clinical application has been developed.

What the research shows

254 findings extracted from the 31 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 9 human trial findings, 15 human study findings, 31 animal findings and 10 expert opinion findings.

  • human trialCB4211 demonstrated robust and significant reductions in Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) biomarkers of liver damage1

  • human trialCB4211 demonstrated significant decrease in glucose levels1

  • human trialCB4211 showed a trend towards lower body weight after four weeks of treatment1

  • human trialCB4211 25 mg dose showed 21% reduction in ALT from baseline compared to 4% in placebo1

  • human trialCB4211 25 mg dose showed 28% reduction in AST from baseline compared to 11% in placebo (p<0.05)1

  • human trialCB4211 showed 6% reduction in glucose from baseline compared to 0% in placebo (p<0.05)1

  • human trialCB4211 achieved 36% responder rate for >30% relative reduction in liver fat content compared to 33% in placebo1

  • human trialCB4211 was tested in Phase 1a/1b (n=88)17

Show the remaining 57

  • human trialA recruiting Phase 2a study is evaluating investigational MOTS-c in adults with prediabetes and overweight or obesity, with insulin sensitivity, metabolic markers, body weight, waist circumference, and safety among the study's measured outcomes23

  • human studyMitochondrial-Derived Peptides (MDPs) have a cytoprotective role in several diseases, including AMD2

  • human studyIn clinical studies, the expression of MOTS-c is decreased in T2DM patients6

  • human studySerum MOTS-c increments within 24 hours post-cardiopulmonary bypass (ΔMOTS-c) predicted ARDS incidence with multivariate models incorporating ΔMOTS-c achieving AUC = 0.8857

  • human studyMOTS-c levels are reduced in both serum and tumor tissues from ovarian cancer patients8

  • human studyReduced MOTS-c levels are associated with poor patient prognosis in ovarian cancer8

  • human studyAcute high intensity exercise in humans can increase concentrations of MOTS-c in skeletal muscle and plasma14

  • human studyEndogenous levels decline with age17

  • human studyEndogenous MOTS-c levels decline with age and in populations with metabolic dysfunction17

  • human studyOnly one small human trial exists - a 4-week study of 20 subjects using CB4211 (a MOTS-C analog, not native MOTS-C)22

  • human studyPhase 1a/1b study showed well-tolerated effects with significant reductions in liver enzymes and glucose levels, plus a trend toward weight loss22

  • human studyMOTS-C levels decline with age (21% lower in 70-81 year-olds)22

  • human studyJapanese centenarians harbor beneficial MOTS-C genetic variants22

  • human studyHuman observational studies have found a link between lower MOTS-c levels and components of metabolic syndrome, like obesity and insulin resistance25

  • human studySmall clinical studies in adults with insulin resistance or prediabetes have shown improved glucose tolerance and metabolic markers after MOTS-C administration over 8–12 weeks26

  • human studyHuman studies had sample sizes under 30 subjects per study and none are placebo-controlled at the scale needed for definitive evidence26

  • animalMOTS-c improves insulin sensitivity in mouse models of type 2 diabetes3

  • animalMOTS-c treatment in mice prevented age-dependent insulin resistance4

  • animalMOTS-c treatment in mice prevented high-fat-diet-induced insulin resistance4

  • animalMOTS-c treatment in mice prevented diet-induced obesity4

  • animalMOTS-c has been shown to improve glucose metabolism in skeletal muscle5

  • animalIntraperitoneal injection of MOTS-c in fed mice significantly reduced blood glucose level and visceral fat with results similar to aerobic exercise6

  • animalMOTS-c and aerobic exercise therapy improved T2DM-induced liver fibrosis in a rat model6

  • animalIn HFD-induced T2DM mice, the TGF-β1/Smad pathway is activated and liver fibrosis is obvious6

  • animalIn a rat model, MOTS-c can inhibit T2DM and reduce oxidative stress and liver fibrosis6

  • animalMOTS-c can modulate antioxidant defence mechanisms during aerobic exercise to reduce diabetic myocardial damage in rat heart tissue6

  • animalMOTS-c has been shown to improve glucose metabolism in skeletal muscle11

  • animalMOTS-c can be an effective treatment for GDM13

  • animalMOTS-c significantly alleviated hyperglycemia in GDM mice13

  • animalMOTS-c improved insulin sensitivity and glucose tolerance in GDM mice13

  • animalMOTS-c reduced birth weight and the death of offspring induced by GDM in mice13

  • animalMOTS-c rejuvenates aging phenotypes in muscle in mice17

  • animalPeripherally administered MOTS-c had no effect on cognition in mice at a dose that improved physical capacity17

  • animalCentrally administered MOTS-c reduces inflammation-based memory problems in mice17

  • animalMOTS-c protects against Aβ42 and LPS-induced memory impairment on novel object recognition and object location recognition tasks in mice17

  • animalAnimal studies consistently demonstrate improved insulin sensitivity, enhanced exercise performance (12-15% improvement in single doses), and metabolic flexibility improvements in various mouse models22

  • animalMice achieved 100% completion rates on exhaustive running tests versus only 16.6% in controls22

  • animalSingle acute doses provided 12-15% performance enhancement22

  • animalAnimal studies show MOTS-C prevents muscle atrophy and enhances muscle insulin sensitivity22

  • animalAnimal studies show trends toward increased lifespan (6-7% improvement)22

  • animalMultiple independent studies using 5 mg/kg daily dosing for 8 weeks documented significant plasma myostatin reductions (p<0.05)22

  • animalIn mouse studies, MOTS-c helped prevent insulin resistance and obesity25

  • animalIn animal models primarily mice fed high-fat diets, MOTS-C improves insulin sensitivity, reduces fat mass and prevents diet-induced obesity26

  • animalMultiple research groups have replicated findings of MOTS-C improving insulin sensitivity in animal models26

  • animalAnimal studies show MOTS-C-treated mice run longer on treadmills and show improved muscle metabolic function26

  • animalAnimal data show MOTS-C treatment can reverse some markers of metabolic aging in older mice26

  • animalPreclinical evidence suggests that MOTS-c improves glucose metabolism, increases mitochondrial density, and enhances fatigue resistance28

  • expert opinionSystemic MOTS-c administration increases exercise performance by boosting skeletal muscle stress responses12

  • expert opinionSystemic MOTS-c administration enhances metabolic adaptation to exercise12

  • expert opinionNone of them have been validated in a published human randomized trial19

  • expert opinionThere is no published human trial that has compared cycle lengths directly19

  • expert opinionThese tiers are summarized from animal studies (Reynolds 2021, Lee 2015, Kumagai 2021)19

  • expert opinionThere have been no patient trials with MOTS-c25

  • expert opinionHuman exercise capacity data is essentially absent26

  • expert opinionNo human trials have evaluated MOTS-C for general healthspan extension or aging-related outcomes26

  • expert opinionMany unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models27

  • expert opinionMOTS-c has the ability to revive oxidatively stressed RPE cells with a significant protective role30

How it works

Based on 4 human trial findings, 1 human study finding, 18 animal findings, 22 in vitro findings, 47 expert opinion findings and 21 theoretical findings.

  • human trialPhase 1a stage was a double blind, placebo-controlled single ascending dose and multiple ascending dose assessment of safety, tolerability, and pharmacokinetics1

  • human trialMOTS-c is a 16-amino-acid peptide encoded by a short open reading frame (sORF) within the mitochondrial 12S rRNA4

  • human trialThe primary target organ of MOTS-c appears to be skeletal muscle4

  • human trialMOTS-c cellular actions inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation4

  • human studyMitochondrial dysfunction contributes significantly to the etiology and pathogenesis of Age-related Macular Degeneration (AMD)2

  • animalMOTS-c exacerbates the senescence-associated-secretory-phenotype (SASP) in senescent cells by stimulating the secretion of IL-6, IL-1β, IL-8, IL-10 and tumor necrosis factor α3

  • animalMOTS-c is widely distributed and expressed in various tissues (brain, heart, liver, muscle, testis, kidney, gut, and plasma) in rodents and humans6

  • animalThe Keap1-Nrf2 pathway is activated by high levels of ROS, aerobic exercise or MOTS-c in T2DM6

Show the remaining 105

  • animalMOTS-c modulates the progression of T2DM complicated by liver fibrosis through a Keap1-Nrf2-Smad2/3 signaling pathway-dependent mechanism6

  • animalMOTS-c is a mitochondrial-derived peptide that acts as a regulator of mitochondrial-nuclear communication7

  • animalMOTS-c mediates endothelial protection against lung ischemia-reperfusion injury (LIRI) through MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes7

  • animalIn rat LIRI models, endothelial cells exhibited the most significant MOTS-c upregulation, correlating with barrier preservation and reduced oxidative stress7

  • animalHypoxia-reoxygenation triggers ROS-dependent phosphorylation of MYH9 at Ser1943 via casein kinase II subunit alpha (CK2A), enabling MOTS-c binding to MYH9-γ-Actin complexes for nuclear transport7

  • animalMOTS-c directly interacts with promoters of antioxidant genes (HMOX1, NQO1) which harbor antioxidant response elements (AREs)7

  • animalMOTS-c regulates the expression of genes such as GLUT4, STAT3, and IL-1010

  • animalMOTS-c is a mitochondrial-derived peptide that can target skeletal muscle and enhance glucose metabolism13

  • animalMOTS-c can activate insulin sensitivity in the skeletal muscle of GDM mice13

  • animalMOTS-c protects pancreatic β-cell from STZ-mediated injury13

  • animalMOTS-c treatment increases antioxidant capacity in mice14

  • animalMOTS-c has exercise mimetic properties14

  • animalExercise and MOTS-c evoke metabolic benefits through distinct and overlapping pathways14

  • animalThe protective effects involve the activation of AMPK signaling and the inhibition of pro-inflammatory cytokines17

  • animalMOTS-C works upstream by inhibiting FOXO1 transcriptional activity, reducing myostatin gene expression through CK2-PTEN-mTORC2-AKT-FOXO1 signaling pathway22

  • in vitroHEK293 cells stably overexpressing MOTS-c had significantly reduced long-chain fatty acids and increased fatty acid utilization compared with normal HEK293 cells6

  • in vitroMOTS-c overexpression or MOTS-c addition to culture medium inhibited ROS levels6

  • in vitroMOTS-c overexpression or MOTS-c addition to culture medium increased mRNA and protein expression of Keap1-Nrf2 pathway genes6

  • in vitroMOTS-c overexpression or MOTS-c addition to culture medium decreased expression of TGF-β1/Smad pathway genes6

  • in vitroExogenous MOTS-c inhibits the proliferation of ovarian cancer cells8

  • in vitroExogenous MOTS-c inhibits migration and invasion of ovarian cancer cells8

  • in vitroExogenous MOTS-c induces cell cycle arrest in ovarian cancer cells8

  • in vitroExogenous MOTS-c induces apoptosis in ovarian cancer cells8

  • in vitroMOTS-c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation8

  • in vitroUSP7 was identified as a deubiquitinase of LARS18

  • in vitroMOTS-c attenuates USP7-mediated LARS1 deubiquitination by competing with USP7 for binding to LARS18

  • in vitroLARS1 is increased in ovarian cancer and plays an important oncogenic function8

  • in vitroMOTS-c is co-expressed with mitochondria in different tissues11

  • in vitroMOTS-c can elevate glucose uptake in vitro13

  • in vitroMOTS-c is a peptide encoded in the mitochondrial genome16

  • in vitroMOTS-c translocates to the nucleus and regulates nuclear gene expression following metabolic stress16

  • in vitroMOTS-c regulates nuclear gene expression in a 5'-adenosine monophosphate-activated protein kinase (AMPK)-dependent manner16

  • in vitroMOTS-c regulated a broad range of genes in response to glucose restriction16

  • in vitroMOTS-c regulated genes with antioxidant response elements (ARE)16

  • in vitroMOTS-c interacted with ARE-regulating stress-responsive transcription factors, such as nuclear factor erythroid 2-related factor 2 (NFE2L2/NRF2)16

  • in vitroMOTS-c acts as a metabolic regulator primarily through activation of the AMP-activated kinase (AMPK), leading to an increase in lipid metabolism and cellular glucose flux17

  • in vitroSkeletal muscle is the primary target organ of MOTS-c17

  • expert opinionMOTS-c is a signal molecule encoded by mitochondrial DNA that was discovered in 2015 and contains 16 amino acids6

  • expert opinionMOTS-c is related to the metabolic regulation of insulin6

  • expert opinionMOTS-c is located mainly in mitochondria in the resting state and is then transferred to the nucleus under the induction of oxidative stress6

  • expert opinionMOTS-c can interact with Nrf2 and participate in antioxidative stress6

  • expert opinionMOTS-c is a mitochondria-derived peptide (MDP) encoded by mitochondrial DNA12

  • expert opinionMOTS-c expression levels increase in skeletal muscles, systemic circulation, and the hypothalamus upon exercise12

  • expert opinionExogenous MOTS-c stimulates thermogenesis in subcutaneous white adipose tissues12

  • expert opinionLow levels of mitochondrial stress are beneficial for organismal health and survival through mitohormesis12

  • expert opinionMOTS-c may be an exercise-sensitive myokine14

  • expert opinionMOTS-c promotes metabolic flexibility and insulin sensitivity17

  • expert opinionMOTS-c may have anti-inflammatory properties and promote cellular energetics17

  • expert opinionMOTS-c is a peptide derived from mitochondrial DNA18

  • expert opinionMOTS-c is a 16-amino-acid peptide that your mitochondria make on their own19

  • expert opinionMOTS-c acts like a chemical signal that tells cells how to handle energy when the body is stressed, exercising, or aging19

  • expert opinionThe most studied effect is that it turns on a protein called AMPK, which is a key energy switch inside cells19

  • expert opinionSmaller, more frequent doses are often described as a way to keep AMPK signaling steadier, since the peptide has a short estimated half-life19

  • expert opinionMOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial derived peptide (MDP), encoded within the mitochondrial genome rather than the nuclear genome20

  • expert opinionWhen cellular stress occurs (e.g., during intense exercise or metabolic challenge), mitochondria release MOTS-c20

  • expert opinionMOTS-c travels out of the mitochondria and into the cytoplasm and nucleus, where it can influence gene expression and cellular function20

  • expert opinionMOTS-c acts as a mitokine, a hormone-like signal that reports on the health status of the mitochondria and orchestrates a coordinated systemic response20

  • expert opinionMOTS-c acts as a key signal from the mitochondria, activating the AMPK master switch to optimize cellular energy and metabolic health20

  • expert opinionThe primary MOTS-c mechanism of action involves activation of 5′ AMP-activated protein kinase (AMPK)20

  • expert opinionAMPK is a central regulator of cellular energy balance that when activated, signals the cell that energy levels are low, triggering processes that increase energy production and reduce energy consumption20

  • expert opinionMOTS-C peptide is a mitochondrial-derived signaling molecule that appears to regulate energy balance, metabolic stress responses, and cellular resilience21

  • expert opinionMOTS-C peptide is transcribed from the mitochondrial genome and then released into the cytosol and nucleus under stress conditions21

  • expert opinionMOTS-C peptide may influence pathways such as AMPK activation and antioxidant gene expression21

  • expert opinionMOTS-C peptide is 16 amino acids long and can traverse cellular membranes and modulate signaling networks21

  • expert opinionMOTS-C peptide was first characterized in 2015 by Lee and colleagues, who showed that stressed muscle cells release this peptide, which then translocates to the nucleus to upregulate genes involved in adaptive stress resistance21

  • expert opinionMOTS-C peptide broadly enhances metabolic homeostasis by targeting AMP-activated protein kinase (AMPK) and antioxidant pathways21

  • expert opinionUnder conditions of low glucose, oxidative stress, or inflammation, mitochondria increase production of MOTS-C21

  • expert opinionMOTS-C enters the nucleus to modulate transcription of genes associated with antioxidant defenses, such as NRF2 targets21

  • expert opinionTheir original research identified MOTS-c as a mitochondrial-derived peptide involved in metabolic signaling, insulin sensitivity, and metabolic homeostasis in preclinical models23

  • expert opinionMOTS-c is a naturally occurring mitochondrial-derived peptide encoded within mitochondrial DNA23

  • expert opinionResearchers have studied its relationship to skeletal muscle, insulin sensitivity, exercise signaling, metabolic homeostasis, and age-related physical decline, although much of the evidence remains preclinical23

  • expert opinionMOTS-c is an injectable peptide derived from mitochondrial DNA25

  • expert opinionMOTS-c is meant to mimic the effects of exercise25

  • expert opinionMOTS-C is a 16-amino-acid peptide encoded inside mitochondria26

  • expert opinionMOTS-C activates AMPK (AMP-activated protein kinase) pathway26

  • expert opinionAMPK activation tells cells to burn fuel more efficiently, become more sensitive to insulin and resist storing excess energy as fat26

  • expert opinionMOTS-C blood levels decline with age26

  • expert opinionEmerging research points to mitochondrial dysfunction as a core contributor to ME/CFS pathology, marked by impaired ATP production, oxidative stress, and bioenergetic failure28

  • expert opinionMOTS-c enhances mitochondrial biogenesis, reduces oxidative damage, and modulates inflammatory responses through AMPK and NRF2 activation28

  • expert opinionDrug hypersensitivity in ME/CFS is thought to stem from underlying mitochondrial dysfunction, altered detoxification pathways, and potential polymorphisms in cytochrome P450 enzymes28

  • expert opinionMOTS-c contributes to browning of white adipose tissue29

  • expert opinionMOTS-c is the most unearthed peptide encoded by mitochondrial DNA (mtDNA)30

  • expert opinionMOTS-c is an important regulator of the nuclear genome during times of stress30

  • expert opinionMOTS-c promotes an adaptive stress response to maintain cellular homeostasis30

  • theoreticalMDPs are encoded within the mtDNA and serve as signals for organism cytoprotection and energy regulation2

  • theoreticalMDPs encoded from the 16S rRNA region of the mtDNA include Humanin and SHL2

  • theoreticalThe human mitochondrial genome is ~16.5 kilobases, circular, double-stranded, and consists of 37 genes that code for 13 proteins of the respiratory chain complexes2

  • theoreticalThe 16S rRNA gene is 1559 bp long, spanning 1671-3229 bp of the mtDNA; it occupies 1/10 of the entire mtDNA and carries ORFs that encode mitochondrial-derived peptides2

  • theoreticalMOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA that plays a cytoprotective role by helping preserve mitochondrial function and cell viability under stressful conditions3

  • theoreticalMOTS-c is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome5

  • theoreticalThe MOTS-c protein is transferred to the nucleus during metabolic stress and directs the expression of nuclear genes to promote cell balance5

  • theoreticalMOTS-c is a short peptide derived from the 12S rRNA of mitochondrial DNA8

  • theoreticalMOTS-c has been suggested as a retrograde mitochondrial signal8

  • theoreticalMOTS-c is expressed from the mitochondrial open reading frame of the 12S ribosomal RNA type-c9

  • theoreticalMOTS-c is associated with regulation of cellular metabolism and insulin action in age-related diseases9

  • theoreticalMOTS-c is a mitochondrial-derived peptide encoded by short open reading frames in the mitochondrial genome10

  • theoreticalMOTS-c has regulatory effects on mitochondrial functions, gene expression, and metabolic homeostasis10

  • theoreticalMOTS-c plays physiological functions mainly through activating the AICAR-AMPK signaling pathways by disrupting the folate-methionine cycle in cells10

  • theoreticalMOTS-c is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome11

  • theoreticalMOTS-c protein is transferred to the nucleus during metabolic stress and directs the expression of nuclear genes to promote cell balance11

  • theoreticalMOTS-c is a peptide encoded within the mitochondrial 12S ribosomal RNA gene15

  • theoreticalMOTS-c can translocate to the nucleus upon metabolic stress (e.g., glucose restriction and oxidative stress)15

  • theoreticalMOTS-c directly regulates adaptive nuclear gene expression to promote cellular homeostasis15

  • theoreticalThe mitochondrial and nuclear genomes co-evolved to independently encode for factors to cross-regulate each other16

  • theoreticalMOTS-c is a 16 amino acid mitochondrial derived peptide encoded by a short open reading frame within 12S rRNA located in the mitochondrial genome17

Dosing

Based on 1 human trial finding, 2 animal findings, 6 expert opinion findings and 1 anecdotal finding.

  • human trialPhase 1b was a randomized, double-blind, placebo-controlled evaluation of one dose level of CB4211 given once a day for four weeks in obese subjects with NAFLD1

  • animalBenefits were only seen when MOTS-c was administered centrally (intracerebroventricularly) or intranasally when coupled to a cell-penetrating carrier17

  • animalAnimal research typically uses 5 mg/kg daily (equivalent to roughly 350mg for a 70kg human)22

  • expert opinionSubcutaneous injection (under the skin) is the format used in animal studies and reported research planning19

  • expert opinionLarger weekly totals do not appear to add benefit in the published animal work and may push side effects higher19

  • expert opinionPractical protocols suggest much lower doses of 5-10mg total per injection22

  • expert opinionMOTS-C administered via subcutaneous injection26

  • expert opinionMOTS-C dosage range 5–10 mg per dose26

Show the remaining 2

  • expert opinionMOTS-C frequency 2–3x weekly26

  • anecdotalCommon research planning: 5 mg, 2 to 3 times per week, for 4 to 8 weeks19

How the body handles it

Based on 2 human study findings, 1 animal finding and 1 in vitro finding.

  • human studyMOTS-c is present in plasma but its level decreases with age11

  • human studyExercise naturally increases endogenous MOTS-C levels by 12-fold in muscle tissue22

  • animalDifferent tissues co-expressed the protein with mitochondria, and plasma also contained the protein, but its level decreased with age5

  • in vitroMOTS-c is not BBB penetrant17

Safety and side effects

Based on 2 human trial findings, 1 animal finding and 18 expert opinion findings.

  • human trialCB4211 was well-tolerated and appeared safe with no serious adverse events in Phase 1a/1b study1

  • human trialCB4211 was safe in a short-term study, but persistent injection site reactions were common17

  • animalMOTS-c displays anti-tumor effect on ovarian cancer growth without systemic toxicity in vivo8

  • expert opinionNo effective method of applying MOTS-c in the clinic has been developed11

  • expert opinionMOTS-c therapeutic safety has not been established17

  • expert opinionMOTS-c may interact with other drugs that target AMPK17

  • expert opinionMOTS-c is not FDA-approved for human use19

  • expert opinionAs of April 22, 2026 it is no longer in FDA Category 2, but it has not been added to the 503A Bulks List19

Show the remaining 13

  • expert opinionWADA bans it at all times19

  • expert opinionClinical use remains experimental, and prescription or injection of MOTS-C peptide should only occur under medical supervision21

  • expert opinionMOTS-c is not FDA-approved for weight loss, obesity, insulin resistance, energy, exercise performance, or another medical or wellness purpose23

  • expert opinionInjection site reactions are mild and transient26

  • expert opinionHeadache is uncommon side effect26

  • expert opinionMild fatigue or flu-like symptoms during initial doses is uncommon26

  • expert opinionPossible blood glucose changes with MOTS-C monitoring recommended for diabetics26

  • expert opinionPregnancy and breastfeeding are absolute contraindications26

  • expert opinionMOTS-C improves insulin sensitivity which can drive blood sugar too low when combined with glucose-lowering medications26

  • expert opinionRigorous human safety data are scarce for unapproved peptides like MOTS-C27

  • expert opinionThere is potential for serious harm to patients from unapproved peptides27

  • expert opinionSafety and efficacy data in humans are lacking for MOTS-c28

  • expert opinionME/CFS patients often experience heightened drug sensitivities and paradoxical reactions that can worsen symptoms28

What people use it for

Based on 1 human trial finding, 6 animal findings, 15 expert opinion findings, 1 anecdotal finding and 14 theoretical findings.

  • human trialMOTS-c regulates insulin sensitivity and metabolic homeostasis4

  • animalMOTS-c has benefits for diseases such as diabetes, obesity, and aging5

  • animalMOTS-c may treat oxidative stress-induced myocardial ultrastructure damage and cardiac dysfunction by activating the Keap1-Nrf2 signalling pathway6

  • animalExogenous MOTS-c administration in rats attenuated lung injury by reducing oxidative damage, inflammation, and mortality7

  • animalMOTS-c treatment of young and aged mice improves exercise capacity/performance14

  • animalMOTS-c treatment leads to weight loss in mice14

  • animalMOTS-c treatment improves insulin sensitivity in mice14

  • expert opinionMDPs merit consideration as therapeutic targets for AMD2

Show the remaining 29

  • expert opinionMOTS-c is regarded as a sport-mimicking substance6

  • expert opinionMOTS-c is the most associated mitochondria-derived peptide with exercise12

  • expert opinionMOTS-c enhances energy expenditure and contributes to anti-obesity effects of exercise training12

  • expert opinionMOTS-c enhances metabolic flexibility, improves insulin sensitivity, and may act as an exercise mimetic17

  • expert opinionMOTS-c may help extend lifespan and improve metabolism while maintaining muscle and losing fat18

  • expert opinionMOTS-c is being evaluated for the treatment of obesity and osteoporosis25

  • expert opinionMOTS-c is mainly studied for metabolism support, insulin resistance, and slower aging25

  • expert opinionMOTS-C (mitochondrial ORF of the 12S rRNA type-c) is a peptide marketed direct to patients27

  • expert opinionMOTS-C operates in a parallel gray market of unapproved compounds largely outside of regulatory oversight27

  • expert opinionMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is characterized by profound fatigue, post-exertional malaise (PEM), and a constellation of immune, neurological, and autonomic symptoms28

  • expert opinionMOTS-c is a mitochondrial-derived peptide with roles in increasing muscle mass29

  • expert opinionMOTS-c improves systemic metabolic function29

  • expert opinionMitochondrial damage and dysfunction have been linked to aging and accelerated cell death associated with many types of retinal degenerations30

  • expert opinionMOTS-c has untapped potential as a treatment for glaucoma, diabetic retinopathy, and age-related macular degeneration30

  • anecdotalPractitioner reports suggest improved workout recovery and endurance26

  • theoreticalMOTS-c is hypothesized to have antiaging activity based on correlative studies3

  • theoreticalMOTS-c can be applied in the treatment of aging, cardiovascular disease, insulin resistance, and inflammation5

  • theoreticalMOTS-c is associated with regulation of cellular metabolism and insulin action in type 2 diabetes mellitus9

  • theoreticalMOTS-c research has relevance to both type 1 and type 2 diabetes9

  • theoreticalMOTS-c could reduce insulin resistance10

  • theoreticalMOTS-c could prevent obesity10

  • theoreticalMOTS-c could improve muscle function10

  • theoreticalMOTS-c could promote bone metabolism10

  • theoreticalMOTS-c could enhance immune regulation10

  • theoreticalMOTS-c could postpone aging10

  • theoreticalMOTS-c indicates benefits for diseases such as diabetes, obesity, and aging11

  • theoreticalMOTS-c has therapeutic potential for aging, cardiovascular disease, insulin resistance, and inflammation11

  • theoreticalMOTS-c has metabolic functions15

  • theoreticalMOTS-C peptide may have potential roles in metabolic health, physical performance, and age-related decline21

Other findings

Based on 4 expert opinion findings.

  • expert opinionMOTS-C is one of several mitochondrial-derived peptides discovered in the past decade21

  • expert opinionMOTS-c was first described in 2015 by researchers at the USC Leonard Davis School of Gerontology working with collaborators from UCLA and the National Institutes of Health23

  • expert opinionMOTS-c received a favorable 7-5 recommendation, with two abstentions, from the FDA's Pharmacy Compounding Advisory Committee concerning potential inclusion of MOTS-c-related substances on the 503A Bulks List23

  • expert opinionMOTS-C was discovered in 201526

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Human evidence is extremely thin and largely from a MOTS-c analog, not native MOTS-c

The only human clinical trial is CohBar's Phase 1a/1b study of CB4211, a MOTS-c analog rather than native MOTS-c, with a small Phase 1b treatment group (n=11 vs n=9 placebo, total enrollment 88). Multiple sources (MOTS-C: Evidence, Legality and How to Approach It — PeptideClarity, FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns, MOTS-c Peptide Dosing Guide: Protocol, Reconstitution & Metabolism (2026), MOTS-C Peptide: Separating Science from Hype | adjust.clinic, MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.) state there are no patient trials with native MOTS-c, human sample sizes are under 30 and none placebo-controlled at definitive scale, and no method of clinical application has been developed. A Phase 2a study in prediabetes/obesity is only recruiting (California Gave the World MOTS-c. Now California Trim Clinic Is Bringing the Conversation Home – News Radio KOTA).

Limited evidence

Nearly all efficacy findings are from animal or in vitro models

Insulin sensitivity, exercise performance, anti-obesity, liver fibrosis, GDM, cancer, lung injury and lifespan findings come from mouse/rat models or cell cultures. Human exercise-capacity data is described as essentially absent (MOTS-C: Evidence, Legality and How to Approach It — PeptideClarity) and safety/efficacy in humans as lacking (Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.).

Single source

CB4211 liver-fat responder rate barely exceeded placebo

CohBar's own trial report shows the headline liver-fat responder rate (36% for >30% relative reduction) was only marginally above placebo (33%), and absolute liver fat reduction was similar (5.03% vs 4.88%), even though ALT/AST and glucose reductions were statistically significant versus placebo. This nuance comes from a single company source.

Contested

Sources give differing dose ranges that don't reconcile

Practical protocols cite 5–10 mg total per injection 2–3x weekly (MOTS-C: Evidence, Legality and How to Approach It — PeptideClarity, MOTS-c Peptide Dosing Guide: Protocol, Reconstitution & Metabolism (2026), MOTS-C Peptide: Separating Science from Hype | adjust.clinic), while animal research uses 5 mg/kg daily (roughly 350 mg extrapolated to a 70 kg human) (MOTS-C Peptide: Separating Science from Hype | adjust.clinic). CohBar's human trial used 25 mg once daily of the CB4211 analog (Nonalcoholic Fatty Liver Disease Clinical Trial). These are large discrepancies and the low doses have not been validated in published human trials.

Contested

MOTS-c effect on inflammation/senescence is mixed across sources

Most sources describe MOTS-c as anti-inflammatory and antioxidant (Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c, MOTS-C Peptide: Benefits, Mechanism, Safety, and Research, MOTS-c, The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.), yet a tier-1 2018 review reports it exacerbates the senescence-associated secretory phenotype by stimulating pro-inflammatory cytokine secretion (IL-6, IL-1β, IL-8, TNFα) in senescent cells (Mitochondrial-Derived Peptides Exacerbate Senescence.).

Limited evidence

Cognitive benefits only occur with central/intranasal delivery; MOTS-c is not BBB-penetrant

The ADDF review notes MOTS-c is not blood-brain-barrier penetrant, peripheral administration had no cognitive effect in mice, and memory protection was seen only with intracerebroventricular or carrier-coupled intranasal delivery.

Preprint

ME/CFS application rests on a preprint

The proposed use of MOTS-c for ME/CFS comes from a 2025 preprint (Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c) that itself states human safety and efficacy data are lacking and warns of heightened drug sensitivities in ME/CFS patients.

Other

Not FDA-approved; regulatory status in flux and banned in sport

Multiple sources note MOTS-c is not FDA-approved for any purpose, was removed from FDA Category 2 effective April 22, 2026 but not added to the 503A Bulks List, received a split 7-5 FDA advisory vote with two abstentions, is banned by WADA at all times, and is sold in a gray market with potential for serious harm.

Single source

Many specific figures come from a single low-tier source

Figures such as 12-15% single-dose performance gains, 100% vs 16.6% treadmill completion, 12-fold exercise-induced increase, 21% lower levels in 70-81 year-olds, 6-7% lifespan improvement and ~40% myostatin reduction all originate from a single tier-3 clinic analysis website (MOTS-C Peptide: Separating Science from Hype | adjust.clinic) and are not independently corroborated in the higher-tier sources.

Single source

Claims that small human studies have proven MOTS-c improves blood sugar are not supported — the only controlled human trials used a modified analog, not MOTS-c itself.

One vendor-published source states that small clinical studies in adults with insulin resistance or prediabetes showed improved glucose tolerance and metabolic markers after 8–12 weeks of MOTS-c administration. No such interventional trials of the natural peptide appear in the medical literature. The only controlled human trial (CohBar's Phase 1a/1b) tested CB4211, a MOTS-c analog rather than MOTS-c itself, and independent reviews — as well as other statements on the same vendor page — say there have been no patient trials with native MOTS-c and that no method of clinical application has been developed.

Using it with other compounds

Check a stack
  • TesamorelinComplementary

    No documented conflict

    Both reduce adiposity, especially visceral and hepatic fat, but through unrelated mechanisms: tesamorelin raises GH/IGF-1 to drive lipolysis, while MOTS-c acts through AMPK-driven metabolism and adipose browning. These non-overlapping fat-loss pathways can complement each other for body-composition goals.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support lipolysis as a shared dimension with complementary (non-overlapping) pathways. MOTS-c mechanisms include AMPK activation, white adipose tissue browning/thermogenesis, and reduced fat mass via metabolic reprogramming. Tesamorelin mechanisms include GH/IGF-1 axis activation driving lipolysis and visceral fat reduction via Gs-alpha/cAMP/PKA signaling. The proposed explanation accurately reflects these distinct mechanistic routes to fat loss, and both peptides are tagged with 'lipolysis,' confirming this shared dimension. The claim that these pathways are unrelated and complementary is well-supported by the non-overlapping receptor targets (NFE2L2/Keap1/AMPK for MOTS-c vs. GHRHR/GH/IGF-1 for tesamorelin) and distinct downstream signaling cascades described in the mechanisms.

    Shares lipolysis

  • SemaglutideComplementary

    No documented conflict

    Both improve glucose handling and drive fat loss but by entirely different mechanisms: semaglutide is a GLP-1 receptor agonist acting on insulin/glucagon and appetite, while MOTS-c works intracellularly via AMPK and improved mitochondrial/glucose metabolism. Combining a central/hormonal metabolic driver with a cellular energy-sensing one is a rational complementary metabolic pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly support a complementary relationship on the shared dimensions of mitochondrial_function and lipolysis. MOTS-c's mechanisms explicitly include AMPK activation, Keap1-Nrf2 antioxidant pathways, and mitochondrial-derived signaling (mitokine), directly supporting mitochondrial_function. Semaglutide's mechanisms include BNIP3-mediated mitochondrial signaling, also supporting mitochondrial_function. Both peptides demonstrate lipolysis effects: MOTS-c via white adipose tissue browning/thermogenesis and reduced fat mass; semaglutide via weight loss and visceral fat reduction. Critically, the mechanisms operate through distinct pathways—MOTS-c via intracellular AMPK/Keap1-Nrf2 and folate-cycle disruption, semaglutide via GLP-1 receptor agonism affecting insulin secretion, glucagon suppression, and appetite—which justifies the 'entirely different mechanisms' claim. The explanation that combining a central/hormonal metabolic driver (semaglutide) with a cellular energy-sensing one (MOTS-c) is rational is well-supported by the provided mechanism material. No contradictions are present.

    Shares mitochondrial function · lipolysis

  • TirzepatideSame downstream effect

    Worth caution

    Tirzepatide (dual GIP/GLP-1 agonist) and MOTS-c both improve insulin sensitivity and reduce fat mass, but through entirely different mechanisms — incretin receptor signaling versus AMPK-driven muscle glucose uptake and fat oxidation. Convergent metabolic output makes them theoretically complementary.

    Tier 4Theoretical — not established
  • SS-31Complementary

    No documented conflict

    Both aim to protect and improve mitochondria but by different routes: MOTS-c works upstream through AMPK activation and Nrf2/ARE antioxidant gene expression, while SS-31 physically stabilizes cardiolipin and the electron-transport-chain supercomplexes to reduce ROS at the source. These are non-overlapping mechanisms converging on the same goal of better mitochondrial function and lower oxidative stress, making them a plausibly synergistic pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly establish both shared dimensions. (1) Mitochondrial_function: MOTS-c improves mitochondrial function via AMPK activation and metabolic pathway modulation (folate-methionine cycle disruption); SS-31 directly stabilizes cardiolipin, ETC supercomplexes, and ATP synthase to enhance oxidative phosphorylation and ATP synthesis. Both target mitochondrial function but through distinct routes. (2) Anti_inflammatory: MOTS-c has anti-inflammatory effects via STAT3/IL-10 regulation and Keap1-Nrf2 pathways; SS-31 modulates inflammation/pyroptosis through ferroptosis suppression and BDNF signaling. The explanation correctly identifies these as non-overlapping upstream (MOTS-c: gene expression/AMPK) versus downstream (SS-31: direct structural/bioenergetic) mechanisms converging on mitochondrial protection and ROS reduction. This is a valid complementary relationship supported by the provided mechanisms.

    Shares mitochondrial function · anti inflammatory

  • BPC-157Complementary

    No documented conflict

    Both engage AMPK and HO-1/antioxidant (HMOX1) cytoprotective signaling. BPC-157 is oriented toward tissue repair and vascular integrity while MOTS-c is metabolic, so overlap is modest but the shared cytoprotective pathways make them compatible rather than conflicting.

    Tier 4Theoretical — not established
  • GHK-CuSame downstream effect

    No documented conflict

    Both engage the Nrf2/PGC-1α antioxidant and AMPK/SIRT1 axes — GHK-Cu through copper-delivered SOD1 support and Nrf2 activation, MOTS-c as a mitochondrial-encoded AMPK activator. They converge on the same antioxidant/metabolic stress-response output from different origins.

    Tier 4Theoretical — not established
  • AOD-9604Complementary

    May be complementary

    MOTS-c improves fat metabolism and drives fat oxidation/adipose browning via AMPK and mitochondrial signaling, while AOD-9604 mobilizes fat by raising cAMP and activating hormone-sensitive lipase. Mobilization (AOD) plus enhanced oxidation (MOTS-c) are logically complementary steps of the same fat-loss process.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support lipolysis-related effects through distinct but complementary pathways. AOD-9604 is explicitly tagged with 'lipolysis' and activates hormone-sensitive lipase via cAMP-PKA signaling to mobilize fat. MOTS-c is also tagged with 'lipolysis' and promotes fat oxidation/browning via AMPK activation and mitochondrial signaling. The proposed explanation accurately reflects the mechanism material: AOD-9604 mobilizes stored fat (lipolysis step), while MOTS-c enhances oxidation of mobilized fat (utilization step). These represent sequential, non-redundant contributions to fat loss that logically complement each other. The shared dimension (lipolysis) is explicitly supported by both peptides' approved tags and their distinct mechanistic contributions to fat metabolism are well-documented in the provided material.

    Shares lipolysis

  • EpithalonComplementary

    No documented conflict

    Both are longevity-oriented peptides converging on antioxidant defense and metabolic/mitochondrial health via distinct mechanisms — MOTS-c drives AMPK/PGC-1α mitochondrial biogenesis and NRF2 antioxidant response, while Epithalon works through telomerase, senescence-pathway, and circadian/antioxidant modulation. Complementary geroprotective strategies.

    Tier 4Theoretical — not established
  • HumaninComplementary

    May be complementary

    Both humanin and MOTS-c are mitochondrial-derived peptides ('mitokines') that signal cellular stress and improve metabolism, but they work through different downstream routes — humanin is chiefly cytoprotective/anti-apoptotic (Bax inhibition, STAT3, PI3K/Akt) while MOTS-c drives AMPK activation and Nrf2 antioxidant responses. Together they cover complementary arms of the same mitochondrial-stress response, which is why they are often discussed as a metabolic/longevity pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish them as mitochondrial-derived peptides (mitokines) with distinct but complementary pathways. Humanin targets anti-apoptotic Bcl-2 family members and activates JAK2/STAT3 and PI3K/Akt, while MOTS-c activates AMPK and the Keap1-Nrf2 antioxidant axis. Both are explicitly tagged with mitochondrial_function and anti_inflammatory in their approved tags. The mechanisms support the claim of complementary action: humanin's cytoprotection via apoptosis inhibition and STAT3 signaling differs from MOTS-c's AMPK-driven metabolic remodeling and Nrf2-mediated antioxidant stress response. Both improve insulin sensitivity and glucose metabolism through different routes, and both are described as mitokines signaling cellular/mitochondrial stress. The shared dimensions (mitochondrial_function, anti_inflammatory) are directly supported by the tagged attributes and mechanism descriptions, and the explanation accurately reflects the distinct downstream pathways documented in each peptide's mechanism material.

    Shares mitochondrial function · anti inflammatory

  • KlothoComplementary

    May be complementary

    Klotho and MOTS-c hit overlapping anti-aging endpoints by different mechanisms. Klotho activates the Nrf2 and FoxO antioxidant programs and suppresses TGF-β/Smad fibrosis and NLRP3 inflammation; MOTS-c is a mitochondrial peptide that activates AMPK and the Keap1-Nrf2 antioxidant axis, improves insulin sensitivity, and also blunts TGF-β1/Smad fibrosis. The shared antioxidant, antifibrotic and insulin-sensitizing outputs make them logically complementary.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly establish complementary anti-inflammatory activity through overlapping pathways. Both peptides activate Nrf2-mediated antioxidant responses (Klotho via Nrf2 antioxidant pathway and FoxO; MOTS-c via Keap1-Nrf2 axis). Both engage TGF-β/Smad signaling (Klotho via TGF-β/Smad2/3; MOTS-c via TGF-β1/Smad and Keap1-Nrf2-Smad2/3 in fibrosis). Both improve insulin sensitivity (Klotho via IGF-1/insulin signaling; MOTS-c via CK2-PTEN-mTORC2-AKT-FOXO1 and GLUT4 regulation). Klotho suppresses NLRP3 inflammasome and NF-κB; MOTS-c shows anti-inflammatory effects and IL-10 gene regulation. The shared dimensions of antioxidant activation, antifibrotic TGF-β modulation, and insulin sensitization are explicitly supported by both mechanism descriptions, justifying the complementary relationship claim.

    Shares anti inflammatory

  • Follistatin-344Same downstream effect

    Worth caution

    MOTS-c is reported to regulate myostatin through a CK2-PTEN-mTORC2-AKT-FOXO1 axis, converging on the same muscle-limiting signal that Follistatin neutralizes directly. Both also add metabolic/anti-inflammatory benefits, so they may reinforce each other on body composition, though this convergence is only weakly characterized.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims both peptides converge on myostatin regulation as a shared downstream mechanism. However, the mechanism descriptions show fundamentally different modes of action: Follistatin directly targets and sequesters myostatin/GDF-8 as a ligand trap, while MOTS-c's connection to myostatin is indirect and occurs through a complex CK2-PTEN-mTORC2-AKT-FOXO1 axis. The MOTS-c description itself notes this pathway 'regulates myostatin' but does not establish that this is a primary or well-characterized mechanism—it appears as one element among many (NRF2, AMPK, GLUT4, STAT3, IL-10). Additionally, while both peptides have 'anti_inflammatory' tags, the mechanisms underlying this effect differ substantially: Follistatin works through TGF-beta superfamily antagonism and SMAD2/3 inhibition, while MOTS-c works through Keap1-Nrf2 antioxidant pathways and AMPK activation. The claim of 'same_downstream' convergence on myostatin is not clearly supported by the provided mechanisms, which show distinct upstream pathways with only speculative indirect overlap on myostatin regulation.

    Shares anti inflammatory

Safety and side effects

Safety overview

Safety data in humans are limited and come mainly from a MOTS-c analog. CohBar reports (src-1) that CB4211 was well-tolerated and appeared safe with no serious adverse events in its Phase 1a/1b study. The ADDF review (src-12) states MOTS-c's therapeutic safety has not been established, that CB4211 was safe in a short-term study but persistent injection-site reactions were common, and that MOTS-c may interact with other drugs targeting AMPK. A 2025 preprint (src-6) and a 2025 review (src-22) both note human safety and efficacy data are scarce; src-22 warns of potential for serious harm and notes MOTS-c operates in a parallel gray market largely outside regulatory oversight.

Reported side effects

A vendor resource (src-2) states MOTS-c side effects include mild, transient injection-site reactions, and uncommonly headache and mild fatigue or flu-like symptoms during initial doses.

Precautions and contraindications

  • The vendor resource (src-2) states MOTS-c can cause blood-glucose changes, so monitoring is recommended for diabetics, and that improved insulin sensitivity can drive blood sugar too low when combined with glucose-lowering medications. It lists pregnancy and breastfeeding as absolute contraindications.
  • The 2025 preprint (src-6) notes ME/CFS patients often experience heightened drug sensitivities and paradoxical reactions, attributed to mitochondrial dysfunction, altered detoxification and potential cytochrome P450 polymorphisms.
  • A 2024 study (src-19) reports MOTS-c showed anti-tumor effects without systemic toxicity in vivo (animal data).

Contested inflammation signal

Most sources describe MOTS-c as anti-inflammatory and antioxidant (src-6, src-11, src-12, src-23). However, a 2018 review (src-31) reports MOTS-c exacerbates the senescence-associated secretory phenotype (SASP) in senescent cells by stimulating secretion of IL-6, IL-1β, IL-8, IL-10 and TNF-α — a nuance that conflicts with the predominant anti-inflammatory framing.

Regulatory and sport status

Multiple sources note MOTS-c is not FDA-approved for any medical or wellness purpose (src-5, src-34, src-44). A clinic press article (src-5) reports a split FDA Pharmacy Compounding Advisory Committee vote (7-5 with two abstentions) regarding possible inclusion of MOTS-c-related substances on the 503A Bulks List. A vendor resource and dosing website (src-2, src-9) state MOTS-c was removed from FDA Category 2 effective April 22, 2026 but has not been added to the 503A Bulks List (src-11 notes a PCAC review date of July 23, 2026). The dosing website (src-9) states WADA bans MOTS-c at all times. A peptide blog (src-11) states clinical use remains experimental and that injection should only occur under medical supervision.

Reconstitution and handling

Dosing

No dose has been established for native MOTS-c. No regulatory label exists for it, and multiple sources state it is not FDA-approved and that no method of clinical application has been developed (src-5, src-17, src-44). The figures below are what sources report — not guidance — and sources do not reconcile with one another.

  • A vendor resource (src-2) describes subcutaneous injection at 5–10 mg per dose, 2–3 times weekly.
  • A dosing-protocol website (src-9) reports common research planning of 5 mg subcutaneously, 2–3 times per week, for 4–8 weeks. It states smaller, more frequent doses are described as a way to keep AMPK signaling steadier given MOTS-c's short estimated half-life, and that larger weekly totals do not appear to add benefit in published animal work and may increase side effects. The same source notes none of these protocols have been validated in a published human randomized trial, no published human trial has compared cycle lengths directly, and the tiers are summarized from animal studies (Reynolds 2021, Lee 2015, Kumagai 2021).
  • A clinic analysis (src-10) notes animal research typically uses 5 mg/kg daily (which it estimates as roughly 350 mg for a 70 kg human), while practical protocols suggest much lower doses of 5–10 mg total per injection.
  • The only human dosing figure comes from CohBar's trial of the analog CB4211 (src-1), which used 25 mg once daily.

These ranges — 5–10 mg total per injection, ~350 mg extrapolated from animal 5 mg/kg dosing, and 25 mg/day of an analog — are large discrepancies, and the low doses have not been validated in published human trials.

Reconstitution arithmetic

The dosing website (src-9) describes reconstituting a 10 mg vial with 1.0 mL bacteriostatic water, which yields a concentration such that a 5 mg dose equals 0.5 mL, or 50 units on a U-100 insulin syringe. This is a calculation about the vial's concentration, not a dosing recommendation.

Administration route

Human/practitioner protocols describe subcutaneous injection (src-2, src-9, src-16). In animal work, intraperitoneal injection is used (src-4, src-25). For cognitive endpoints specifically, the ADDF review (src-12) notes peripheral administration was ineffective in mice and that MOTS-c is not blood-brain-barrier penetrant, with effects seen only via intracerebroventricular or carrier-coupled intranasal delivery.

Sources

Ordered by evidence quality — the strongest first.

  1. Nonalcoholic Fatty Liver Disease Clinical Trial(opens in a new tab)
    Tier 1Web · cohbar.com
  2. Effects of Mitochondrial-Derived Peptides (MDPs) on Mitochondrial and Cellular Health in AMD(opens in a new tab)
    Tier 1Web · doi.org · 2020
  3. Mitochondrial-Derived Peptides Exacerbate Senescence.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  4. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2015
  5. MOTS-c: A promising mitochondrial-derived peptide for ... - PMC(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  6. MOTS-c mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3(opens in a new tab)
    Tier 2Web · doi.org · 2025
  7. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  8. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  9. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  10. MOTS-c Functionally Prevents Metabolic Disorders.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  11. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  12. Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c).(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  13. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  14. Mitochondrial-derived peptides and exercise.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  15. MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  16. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  17. MOTS-c(opens in a new tab)
    Tier 3Web · alzdiscovery.org
  18. MOTS-c Peptide | Benefits, Safety, & Buying Advice [2026](opens in a new tab)
    Tier 3Web · innerbody.com
  19. MOTS-c Peptide Dosing Guide: Protocol, Reconstitution & Metabolism (2026)(opens in a new tab)
    Tier 3Web · peptidedosingprotocols.com
  20. MOTS-c Peptide Therapy: The Definitive 2025+ Blueprint for Metabolic Health & Longevity(opens in a new tab)
    Tier 3Web · ipharmapharmacy.com
  21. MOTS-C Peptide: Benefits, Mechanism, Safety, and Research(opens in a new tab)
    Tier 3Web · helimeds.com
  22. MOTS-C Peptide: Separating Science from Hype | adjust.clinic(opens in a new tab)
    Tier 3Web · adjust.clinic
  23. California Gave the World MOTS-c. Now California Trim Clinic Is Bringing the Conversation Home – News Radio KOTA(opens in a new tab)
    Tier 3Web · lifestyle.kotaradio.com · 2026
  24. Financial News | myMotherLode.com - California Gave the World MOTS-c. Now California Trim Clinic Is Bringing the Conversation Home(opens in a new tab)
    Tier 3Web · money.mymotherlode.com · 2026
  25. FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns(opens in a new tab)
    Tier 3Web · health.com · 2026
  26. MOTS-C: Evidence, Legality and How to Approach It — PeptideClarity(opens in a new tab)
    Tier 3Web · getpeptideclarity.com · 2026
  27. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  28. Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c(opens in a new tab)
    Tier 3Web · doi.org · 2025
  29. Exercise-Induced Muscle-Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  30. Mitochondrial Open Reading Frame of the 12S rRNA Type-c: Potential Therapeutic Candidate in Retinal Diseases.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  31. Thời Sự Buổi Sáng | 08/05/2026 | FULL🔴(opens in a new tab)
    Tier 4Web · youtube.com